🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Cabaletta Bio, Inc.

Cabaletta Bio, Inc. logo
Market Cap: Low
Employees: Low

DSG3-CAART

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.

Tags: CAAR T cells, T cell therapies, autoimmune diseases, biotechnology, clinical trials

Website

About | Leadership | Directors | About | About | About | About | Contact | About | About

Symbol: CABA

Recent Price: $2.24

Industry: Biotechnology

CEO: Dr. Steven A. Nichtberger M.D.

Sector: Healthcare

Employees: 136

Address: 2929 Arch Street, Philadelphia, PA 19104

Phone: 267 759 3100

Leadership

  • Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
  • Samik Basu, M.D., Chief Scientific Officer
  • Gwendolyn Binder, Ph.D., President, Science & Technology
  • David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
  • Arun Das, M.D., Chief Business Officer
  • Michael Gerard, General Counsel
  • Heather Harte-Hall, Chief Compliance Officer
  • Anup Marda, Chief Financial Officer
  • Martha O’Connor, Chief Human Resources Officer
  • Sarah Yuan, Ph.D., Chief Technology Officer
  • Catherine Bollard, M.D., Independent Director, George Washington University
  • Scott Brun, M.D., Independent Director, formerly at AbbVie
  • Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
  • Mark Simon, M.B.A., Independent Director, Torreya Partners
  • Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.

Last updated: 2024-12-31